The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle ...

New University of Virginia School of Medicine research revealing the fingerprints of Sudden Infant Death Syndrome (SIDS) ...

This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...

Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating ...

While nicotine is known to enhance platelet aggregation, its effects on other platelet functions and underlying mechanisms remain unclear. Discussion: In conclusion, nicotine activates αIIbβ3 ...

National Institutes of Health (NIH) Director Monica Bertagnolli will resign on Jan. 17, she told staff this week, ending her tenure as the head of the $48 billion biomedical research agency after ...

Human platelet lysates (HPL) are abundant in bioactive factors, and numerous studies have demonstrated their beneficial effects on neurological diseases, including their anti-neuroinflammatory ability ...